Hypothesis on functional inadequacy of thioredoxin and related systems in preeclampsia

Hypertension in Pregnancy

Volumn 16, Issue 1, 1997, Pages 35-46

  Stark, Marshall ^a   Neale, Lynne ^a   Woodhead, Stuart ^a   Jasani, Bharat ^a   Johansen, Karl A ^b   Shaw, Robert W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Estrogens; Gonadotrophin; Nitric oxide; PET; Thioredoxin

Indexed keywords

CYTOKINE; ESTROGEN; GONADOTROPIN; HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; THIOL GROUP; THIOREDOXIN; THIOREDOXIN REDUCTASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; PLACENTA; PREECLAMPSIA; UTERUS;

EID: 0030896594     PISSN: 10641955     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641959709069088     Document Type: Article

References (61)

1. Chen HL, Yang Y, Hu X-L, Yelavarthi KK, Fishback LL, Hunt JS. Tumor necrosis factor alpha mRNA and protein are present in human placental and uterine cells at early and late stages of gestation. Am J Pathol 1991;139:327-35.
2. Witkin SS, Liu H-C, Davis OK, Rosenvaks Z. Tumor necrosis factor is present in maternal sera and embryo culture fluids during in vitro fertilization. J Reprod Immunol 1991;19:85-93.
3. Hill JA. Cytokines considered critical in pregnancy. Am J Reprod Immunol 1992;28: 123-6.
4. Schroecksnadel H, Herold M, Steckel-Berger G, Fuchs D, Wachter H, Dapunt O. Zellvermittelte Immunitaet bei schwangerschaftsinduzierten Hochdruckerkrankungen. Geburtsh Frauenheilk 1992;52:592-5.
5. Kupfermine MJ, Peaceman AM, Wigton TR, Rehnberg KA, Socol M. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe pre-eclampsia. Am J Obstet Gynecol 1994;170:1752-9.
6. Vince G, Starkey PM, Austgulen R, Kwiatkowski D, Redman CWG. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995;102:20-5.
7. Keith JC, Rowles TK, Dilorenzo K, Mishra S, Misra HP. [untitled] J Perinatal 1993; 13:417-8.
8. Visser W, Beckmann I, Bremer HA, Lim HL, Wallenburg HCS. Bioactive tumour necrosis factor alpha in pre-eclamptic patients with and without the HELLP syndrome. Br J Obstet Gynaecol 1994;101:1081-2.
9. Keith JC, Pijnenborg R, Spitz B, Hanssens M, van Assche FA. Assessment of differential serum cytotoxicity in gestational hypertension using a fibrosarcoma cell line and the MTT assay. Hypertens Pregnancy 1994;14:81-90.
10. Greer IA, Lyall F, Perera T, Boswell F, Macara M. Increased concentrations of cytokines IL6 and IL1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction. Obstetrics Gynecol 1994;84:937-40.
11. Schiff E, Friedman SA, Baumann P, Sibai BM, Romero R. Tumor necrosis factor-alpha in pregnancies associated with preeclampsia or small for gestational-age newborns. Am J Obstet Gynecol 1994;170:1224-9.
12. Meekins JW, McLaughlin PJ, West DC, McFadyen IR, Johnson PM. Endothelial cell activation by tumour necrosis factor-alpha and the development of pre-eclampsia. Clin Exp Immunol 1994;98:110-4.
13. Stark M, Jones SJ, Johansen K, Blake L, Shaw R. Tumour necrosis factor. Lancet 1995;345:648.
14. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLauchlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200-4.
15. Roberts JM, Redman CWG. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993;341:1447-51.
16. Stark JM: Pre-eclampsia and cytokine-induced oxidative stress. Br J Obstet Gynaecol 1993;100:105-9.
17. Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W. Cytotoxic activity of tumour necrosis factor is mediated by early damage of mitochondrial functions: evidence for the involvement of mitochondrial radical generation. J Biol Chem 1992;267:5317-23.
18. Feingold KR, Serio MK, Adi S, Moser AH, Grunfeld C. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology 1989;124:2336-42.
19. Gamble JR, Smith WB, Vadas MA. TNF modulation of endothelial and neutrophil adhesion. In: Beutler B, ed. Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. New York: Raven Press, 1992:65-86.
20. Clauss M, Ryan J, Stern D. Modulation of endothelial cell hemostatic properties by TNF: insights into the role of endothelium in the host response to inflammatory stimuli. In: Beutler B, ed. Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. New York: Raven Press, 1992:49-64.
21. van der Poll T, van Deventer SJ, Pasterkamp G, van Mourik JA, Buller HR, ten Cate JW. Tumor necrosis factor induces von Willebrand factor release in healthy humans. Thromb Haemostasis 1992;67:623-6.
22. Austgulen R, Lien E, Liabbakk N-B, Jacobsen G, Arntzen KJ. Increased levels of cytokines and cytokine activity modifiers in normal pregnancy. Eur J Obst Gynecol Reprod Biol 1994;57:149-55.
23. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem 1989;284:13963-6.
24. Mitchell MD, Lundin-Schuller S, Edwin SS. Endothelin production by amnion and its regulation by cytokines. Am J Obstet Gynecol 1991;165:120-4.
25. Lamas S, Michel T, Brenner BM, Marsden PA. Nitric oxide synthesis in endothelial cells: evidence for a pathway inducible by TNF-alpha. Am J Physiol 1991;261: C634-41.
26. Lyall F, Young A, Greer I. Nitric oxide concentrations are increased in the fetoplacental circulation in preeclampsia. Am J Obstet Gynecol 1995;173:714-8.
27. Sambucetti LC, Cherrington JM, Wilkinson GWG, Mocarski ES. NF-kB activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J 1989;8:3251-8.
28. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991; 19:2499.
29. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kB transcription factor and HIV-1. EMBO J 1991;10:2247-58.
30. Israel N, Gougerot-Pocidalo M-A, Aillet F, Virelizier J-L. Redox status of cells influences constitutive or induced NF-kB translocation and HIV long terminal repeat activity in human T and monocyte cell lines. J Immunol 1992;149:3386-93.
31. Zabel U, Baeuerle P. Purified human IkB can rapidly dissociate the complex of the NF-kB transcription factor with its cognate DNA. Cell 1990;61:255-65.
32. Zabel U, Schreck R, Baeuerle PA. DNA binding of purified transcription factor NF-kB. J Biol Chem 1991;266:252-60.
33. Orozco C, Clark IQ, Cock IE, Clarke FM. A description of the basic system of components in pregnant mice sera responsible for "early pregnancy factor" activity. J Reprod Fertil 1994;100:291-7.
34. Morton H, Rolfe B, Clunie GJA. An early pregnancy factor detected in human serum by the rosette inhibition test. Lancet 1979;1:394-7.
35. cdc2 kinase activation in mouse two-cell block. Biochim Biophys Acta 1993;1176:90-4.
36. Kobayashi F, Sagawa N, Nanbu Y, Kitaoka Y, Mon T, Fujii S, Nakamura H, Masutani H, Yodoi J. Biochemical and topological analysis of adult T-cell leukemia-derived factor, homologous to thioredoxin, in the human uterus. Human Reproduction 1995; 10:1603-8.
37. Perkins AV, Di Trapani G, McKay MS, Clarke FM. Immunochemical localization of thioredoxin in human trophoblast and decidua. Placenta 1995;16:635-42.
38. Grippo JF, Holmgren A, Pratt WB. Proof that the endogenous, heat-stable glucocorticoid receptor activating factor is thioredoxin. J Biol Chem 1985;260:93-7.
39. 2 upon thioredoxin-enriched lens epithelial cells. J Biol Chem 1985;263: 4984-90.
40. Fernando MR, Nanri H, Yoshitake S, Nagata-Kuno K, Minakami S. Thioredoxin regenerates proteins inactivated by oxidative stress in endothelial cells. Eur J Biochem 1992;209:917-22.
41. Matthews JR, Wakasugi N, Virelizier J-L, Yodoi J, Hay RT. Thioredoxin regulates the DNA binding activity of NF-kB by reduction of a disulphide bond involving cysteine 62. Nucl Acids Res 1992;20:3821-30.
42. Schenk H, Vogt M, Droege W, Schulze-Osthoff K. Thioredoxin as a potent costimulus of cytokine activity. J Immunol 1996;156:765-71.
43. Schenk H, Klein M, Erdbrugger W, Droge W, Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc Natl Acad Sci USA 1994;91:1672-6.
44. Matsuda M, Masutani H, Nakamura H, Miyajima S, Yamuchi A, Yonehara S, Uchida A, Irijami K, Horiuchi A, Yodoi J. Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells. J Immunol 1991;147:3837-41.
45. Wakasugi N, Tagaya Y, Wakasugi H, Mitsui A, Maeda M, Yodoi J, Tursz T. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci USA 1990;87:8282-6.
46. Bjornstedt M, Xue X, Huang W, Akesson B, Holmgren A. The thioredoxin and glutaredoxin systems are efficient electron donors to human plasma glutathione peroxidase. J Biol Chem 1994;269:29382-4.
47. Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett 1987;210:37-9.
48. Nakano M, Sugioka K, Naito I, Takekoshi S, Niki E. Novel and potent biological antioxidants on membrane phospholipid peroxidation: 2-hydroxy estrone and 2-hydroxy estradiol. Biochem Biophys Res Commun 1987;142:919-24.
49. Mazière C, Auclair M, Ronveaux M-F, Salmon S, Santus R, Mazière J-C. Estrogens inhibit copper and cell-mediated modification of low density lipoprotein. Atherosclerosis 1991;89:175-82.
50. Maruyama T, Sachi Y, Furuke K, Kitaoka Y, Tanaguiueda Y, Nakajima S, Nakanoin K, Yodoi J. Hormonal regulation of human thioredoxin adult T-cell leukaemia derived factor (HTRX/ADF) expression in human endometrium in vivo and in vitro [abstract]. Biol Reprod 1995;52:S1-200.
51. Carbarns NJB, Neale ML, Stark JM. Protective effect of an oestrogen against endotoxin-induced liver enzyme release. Int J Exp Path 1993;74:309-14.
52. Danenberg HG, Albert G, Lustig S, Ben-Nathan D. Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production. Antimicrob Agents Chemother 1992;36:2275-9.
53. Long PA, Abell DA, Beischer NA. Fetal growth and placental function assessed by urinary estriol excretion before the onset of preeclampsia. Am J Obstet Gynecol 1979;135:344-7.
54. Gant NF, Hutchinson HT, Siiteri PK, Macdonald PC. Study of the metabolic clearance rate of dehydroepiandrosterone sulfate in pregnancy. Am J Obstet Gynecol 1971; 111:555-61.
55. Chesley LC. Hypertensive Disorders of Pregnancy. New York: Appleton-Century-Crofts, 1978:455.
56. Fuchs F, Klopper A. Endocrinology of Pregnancy, 3rd ed Philadelphia: Harper and Row, 1983:123.
57. Laverty CRA, Fortune DW, Beischer NA. Congenital idiopathic adrenal hypoplasia. Obstetrics Gynecol 1973;41:655-64.
58. Harbour-McMenamin D, Smith EM, Blalock JE. Production of immunoreactive chorionic gonadotropin during mixed lymphocyte reactions: a possible selective mechanism for genetic diversity. Proc Natl Acad Sci USA 1986;83:6834-8.
59. Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BME, Jakobs C, van Geijn H. Underlying disorders associated with severe early onset preeclampsia. Am J Obstet Gynecol 1995;175:1042-5.
60. Cha MK, Kim I-H. Thioredoxin-linked peroxidase from human red blood cell: evidence for the existence of thioredoxin and thioredoxin reductase in human red blood cell. Biochim Biophys Res Commun 1995;217:900-7.
61. Jia L, Bonaventura C, Bonaventura J, Stamler JS. 5-Nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 1996;380:221-6.